Bruxism

07/16/2011 - "Botulinum toxin A infiltrations are a safe and useful treatment for patients with severe bruxism."
02/01/2012 - "Electronic databases (PubMed, Embase and Science Citation Index), websites (Cochrane Central Register of Controlled Trials and ClinicalTrials.gov) and the literature database of SIGLE (System for Information on Grey Literature in Europe) were searched from January 1990 to April 2011 for randomised controlled trials or nonrandomised studies assessing the efficacy of botulinum toxins on bruxism. "
02/01/2012 - "The objective of this study was to assess the efficacy of botulinum toxins on bruxism. "
02/01/2012 - "Efficacy of botulinum toxins on bruxism: an evidence-based review."
03/01/2014 - "Although the follow-up period of patients was relatively short and the sample quite small, the general impression, confirmed by the patients' experience, seems to suggest a potential place for the use of botulinum toxin amongst the array of treatments which can be offered in certain selected cases which associate bruxism and posterior cervical contractions. "

11/01/1996 - "This case suggests paroxetine-induced bruxism. "
11/01/1996 - "Possible paroxetine-induced bruxism."
01/01/2007 - "Paroxetine-induced bruxism effectively treated with tandospirone."
11/01/1996 - "To report the case of a patient with possible paroxetine-induced bruxism that was effectively treated with buspirone. "
11/01/1996 - "Clinicians should be aware that the potential for paroxetine-induced bruxism exists and that buspirone may be an appropriate therapeutic intervention."

12/01/2014 - "The use of Botox is a minimally invasive procedure and is showing quite promising results in management of muscle-generated dental diseases like Temporomandibular disorders, bruxism, clenching, masseter hypertrophy and used to treat functional or esthetic dental conditions like deep nasolabial folds, radial lip lines, high lip line and black triangles between teeth. "
02/01/2013 - "The findings suggest that there is level 1 evidence supporting the efficacy of Botox in the treatment of spasmodic dysphonia, essential voice tremor, headache, cervical dystonia, masticatory myalgia, sialorrhoea, temporomandibular joint disorders, bruxism, blepharospasm, hemifacial spasm and rhinitis. "

02/01/1997 - "Bruxism secondary to antipsychotic drug exposure: a positive response to propranolol."
02/01/1997 - "The positive response of iatrogenic bruxism to propranolol implies that propranolol also deserves a trial for the treatment of noniatrogenic nocturnal bruxism."
02/01/1997 - "Both complications were relieved after the beta-adrenergic blocker propranolol was added, suggesting the involvement of the adrenergic and serotonergic central nervous systems, besides the dopaminergic system, in the pathogenesis of bruxism. "
01/01/2014 - "Studies evaluating bromocriptine, clonidine, propranolol and levodopa reported our primary outcome of indices of bruxism motor activity.Results"
01/01/2014 - "These were the specific findings for each of the drugs according to specific outcomes: 1. Amitriptyline versus placebo for masseteric electromyography (EMG) activity per minute: standardized mean difference (SMD) -0.28 (95% confidence interval (CI) -0.91 to 0.34; P value = 0.37), 2. bromocriptine versus placebo for bruxism episodes per hour: mean difference (MD) 0.60 (95% CI -2.93 to 4.13), bruxism bursts per hour: MD -2.00 (95% CI -53.47 to 49.47), bruxism bursts per episode: MD 0.50 (95% CI -1.85 to 2.85) or number of episodes with grinding noise: MD 2.40 (95% CI -24.00 to 28.80), 3. clonidine versus placebo for number of bruxism episodes per hour: MD -2.41 (95% CI -4.84 to 0.02), 4. propranolol versus placebo for the number of bruxism episodes per hour: MD 1.16 (95% CI -1.89 to 4.21), 5. L-tryptophan versus placebo for masseteric EMG activity per second: SMD 0.08 (95% CI -0.90 to 1.06) and 6. levodopa versus placebo for bruxism episodes per hour of sleep: MD -1.47 (95% CI -3.64 to 0.70), for bruxism bursts per episode: MD 0.06 (95% CI -2.47 to 2.59).We combined several secondary outcomes (sleep duration, masseteric EMG activity per minute and pain intensity) in a meta-analysis for comparison of amitriptyline with placebo. "

01/01/1997 - "L-Dopa resulted in a significant decrease in the average number of bruxism episodes per hour of sleep, as well as in a significant reduction in the average value of the root-mean-square (RMS) electromyography (EMG) level per bruxism burst. "
03/01/2004 - "The bruxism responded favourably to low-dose levodopa-carbidopa therapy. "
01/01/2014 - "Studies evaluating bromocriptine, clonidine, propranolol and levodopa reported our primary outcome of indices of bruxism motor activity.Results"
01/01/2014 - "These were the specific findings for each of the drugs according to specific outcomes: 1. Amitriptyline versus placebo for masseteric electromyography (EMG) activity per minute: standardized mean difference (SMD) -0.28 (95% confidence interval (CI) -0.91 to 0.34; P value = 0.37), 2. bromocriptine versus placebo for bruxism episodes per hour: mean difference (MD) 0.60 (95% CI -2.93 to 4.13), bruxism bursts per hour: MD -2.00 (95% CI -53.47 to 49.47), bruxism bursts per episode: MD 0.50 (95% CI -1.85 to 2.85) or number of episodes with grinding noise: MD 2.40 (95% CI -24.00 to 28.80), 3. clonidine versus placebo for number of bruxism episodes per hour: MD -2.41 (95% CI -4.84 to 0.02), 4. propranolol versus placebo for the number of bruxism episodes per hour: MD 1.16 (95% CI -1.89 to 4.21), 5. L-tryptophan versus placebo for masseteric EMG activity per second: SMD 0.08 (95% CI -0.90 to 1.06) and 6. levodopa versus placebo for bruxism episodes per hour of sleep: MD -1.47 (95% CI -3.64 to 0.70), for bruxism bursts per episode: MD 0.06 (95% CI -2.47 to 2.59).We combined several secondary outcomes (sleep duration, masseteric EMG activity per minute and pain intensity) in a meta-analysis for comparison of amitriptyline with placebo. "
01/01/1979 - "Aggression and bruxism were not equally successfully induced after L-dopa given with a peripheral inhibitor of aromatic amino acid decarboxylase (benserazide) or when L-dopa treatment was modified with the inhibitor of dopamine-beta-hydroxylase (diethyldithiocarbamate) or monoamine oxidase inhibitor (iproniazid). "

03/01/2013 - "These reports suggest that hydroxyzine may be effective for the treatment of bruxism in children. "
03/01/2013 - "It is worthwhile conducting placebo-controlled studies investigating the possible role of hydroxyzine for the treatment of bruxism in children. "
06/01/2013 - "Current evidence support that hydroxyzine is effective and well tolerated for treating bruxism in children."
06/01/2013 - "Hydroxyzine more than placebo decreased bruxism score (3·8 versus 2·2). "
05/01/2013 - "Treatment of bruxism with hydroxyzine: a possible mechanism of action."

12/01/2011 - "Buspirone for bruxism in a child with pervasive developmental disorder-not otherwise specified."
08/01/2006 - "Antidepressant-induced bruxism: need for buspirone?"
12/01/1999 - "All 4 responded to adjunctive buspirone, a serotonin-1A (5-HT1A) receptor agonist, with relief of bruxism and associated symptoms. "
12/01/1999 - "Buspirone as an antidote to SSRI-induced bruxism in 4 cases."
11/01/1996 - "According to published reports, SSRI-induced bruxism may respond to therapy with buspirone. "

03/01/2009 - "After venlafaxine withdrawal, bruxism improved gradually and disappeared 2 months later. "
03/01/2009 - "Bruxism should be considered as a possible adverse effect of venlafaxine."
03/01/2009 - "A 62-year-old man developed severe bruxism that began 2 weeks after starting a therapy with venlafaxine because of depression and anxiety. "
03/01/2009 - "To report a patient with bruxism possibly induced by the antidepressant venlafaxine. "
03/01/2009 - "Bruxism possibly induced by venlafaxine."

12/01/2013 - "Mast cells were present around blood vessels and nerves in the epimysium and perimysium of MM. These results, together with others reported previously, suggest that: (i) peripheral histamine supports strenuous MM activity; (ii) strenuous MM activity stimulates mast cells to release histamine and to induce HDC (which replenishes the histamine pool in mast cells, possibly mediated by IL-1); and (iii) peripheral histamine H1 receptor antagonists may be effective in treating temporomandibular disorders or preventing prolonged clenching and/or bruxism. "
10/01/2014 - "The term 'bruxism' was used in association with 'psychotropic', 'dopamine (DA)', 'serotonin', 'histamine', 'antipsychotics', 'antidepressants', 'antihistaminergics' and 'stimulants'. "

01/01/2005 - "Acute clonazepam therapy significantly improved not only the bruxism index but also objective and subjective sleep quality, with unchanged mood, performance and psychophysiological measures upon awakening, suggesting good tolerability of the drug."
01/01/2005 - "As compared with placebo, 1 mg clonazepam significantly improved the mean bruxism index from 9.3 to 6.3/h of sleep. "
10/01/2007 - "The NNT could not be calculated for an alternative pharmacologic treatment, short-term clonazepam therapy, which had a large effect size and reduced the average bruxism index. "

01/01/2008 - "Two RCTs concentrated on electromyographic (EMG) investigations in patients with TMDs and concomitant bruxism (Baad-Hansen et al 2007, Jadad score: 4) or with bruxism alone (Kavakli 2006, Jadad score: 2); in both studies, compared to an occlusal stabilization splint the NTI-tss device showed significant reduction of EMG activity. "
08/01/2013 - "This study was aimed to identify differences in the responses of individuals with bruxism and healthy individuals to a full-arch maxillary stabilization splint in terms of occlusal changes. "
06/01/2011 - "This study aimed to evaluate the long-term outcome of arthrocentesis and stabilizing splints for the treatment of acute closed lock in patients with bruxism. "
04/01/2005 - "This study aimed to demonstrate the difference in responses between bruxism and a subgroup of TMD to a full-arch maxillary stabilization splint from the standpoint of an occlusal condition. "
01/01/2003 - "Bruxism-type forces, i.e., forceful tooth-to-splint contacts, during the night were recorded with this system in 12 subjects (6 bruxers and 6 controls) for 5 nights in their home environment; a laboratory-based nocturnal polysomnogram (NPSG) study was also performed on 1 of these subjects. "

10/01/1977 - "A highly significant reduction in bruxism has been obtained using a biofeedback system. "
12/01/1982 - "The results from multiple indices of bruxism are internally consistent and indicate that simple nocturnal biofeedback does not appear to be effective in reducing nocturnal bruxing. "
02/01/2013 - "[Preliminary study of wireless biofeedback therapy for treatment of bruxism]."
04/01/2015 - "The mini wireless biofeedback method may be of value for the diagnosis and management of bruxism in the future. "
01/01/2014 - "Biofeedback is not new, but its place in the clinical management of bruxism remains unclear. "

02/01/1993 - "Origins of the false failures seem to be more related to patient factors like caries activity, caries susceptibility and oral hygiene, but chewing habits (bruxism) may also play a role."
01/01/2013 - "Inclusion criteria are adults who need an inlay/onlay restoration for one tooth (that can be isolated with use of a dental dam and has at least one intact cusp), can tolerate restorative procedures and do not have severe bruxism, periodontal or carious disease or poor oral hygiene. "
05/01/2013 - "The determinant factors for oral mucosal conditions were the female gender, age between 3 and 5 years, inadequate oral hygiene, low household income, residence in rural areas and presence of dental caries and bruxism."
02/01/1992 - "Different environmental factors considered, such as food habits, exposure to infection, oral hygiene habits, bruxism, access to professional dental care, and habits as to seeking dental treatment, did not seem to account for or to have any influence on the observed phenotypic correlation between TM and more favorable bone height. "
07/01/2004 - "We found statistically significant decreases in muscle spasticity and bruxism (p = 0.002), improved inter-incisal opening (p = 0.002), improved oral hygiene (p = 0.031), and less lower lip trauma (p = 0.060) after the neuromuscular blocking."

10/01/2005 - "Statistical comparisons of the MAS responses before and after treatment (at 1-month recall) showed significant improvement (P<.05) for all teeth-related signs and symptoms except for bruxism (P=.0699). "
11/01/2014 - "All patients showed improvement in bruxism after treatment. "
06/01/1989 - "As part of a bruxism treatment study, we evaluated 100 nocturnal bruxers for bruxing activity before, during, and immediately after treatment and again at a six-month recall. "
02/01/2013 - "Statistically significant reductions in the number of SB episodes per hour and per night, bruxism time index, total duration of SB episodes per night and number of SB episodes in stages NR I and NR II (p < 0.05) were observed in both groups after treatment. "
09/01/1987 - "Comparing the EEG-findings of bruxism after treatment to those of the healthy controls, no significant differences were found anymore."

12/01/2012 - "The patient in this study responded positively to a combination of BoNT-A and manual therapy, resulting in decreased masseter muscles spasticity and improved trismus and bruxism."